Neuronetics (STIM) Stock Price
Neuronetics Price
Over the last 9 years Neuronetics grew revenue by 17.8% annually, reaching 149.16 M USD. For Neuronetics, the net margin of -26.1% is up versus -56.4% a few years ago. The consensus 12-month price target for Neuronetics is 3.06 USD, about 6.2% above where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 144% above its 52-week low.
Neuronetics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Neuronetics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Neuronetics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Neuronetics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Neuronetics Price |
|---|---|
| 9/4/2026 | 2.88 USD |
| 9/3/2026 | 2.72 USD |
| 9/2/2026 | 2.77 USD |
| 9/1/2026 | 2.84 USD |
| 8/31/2026 | 2.84 USD |
| 8/30/2026 | 2.89 USD |
| 8/28/2026 | 2.96 USD |
| 8/27/2026 | 2.98 USD |
| 8/26/2026 | 3.00 USD |
| 8/25/2026 | 2.98 USD |
| 8/24/2026 | 2.91 USD |
| 8/21/2026 | 3.00 USD |
| 8/20/2026 | 3.09 USD |
| 8/19/2026 | 3.10 USD |
| 8/18/2026 | 3.20 USD |
| 8/17/2026 | 3.27 USD |
| 8/14/2026 | 3.30 USD |
| 8/13/2026 | 3.03 USD |
| 8/12/2026 | 3.17 USD |
| 8/10/2026 | 2.17 USD |
| 8/7/2026 | 2.38 USD |
| 8/6/2026 | 2.25 USD |
| 8/5/2026 | 2.22 USD |
| 8/4/2026 | 2.24 USD |
| 8/3/2026 | 2.16 USD |
| 7/31/2026 | 1.98 USD |
| 7/30/2026 | 1.97 USD |
| 7/29/2026 | 1.88 USD |
| 7/27/2026 | 1.75 USD |
| 7/23/2026 | 1.88 USD |
Neuronetics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Neuronetics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34.00 | 40.00 | 52.00 | 62.00 | 49.00 | 55.00 | 65.00 | 71.00 | 74.00 | 149.00 | 161.00 | 176.00 | 190.00 | 206.00 | 223.00 |
| – | 17.65 | 30.00 | 19.23 | -20.97 | 12.24 | 18.18 | 9.23 | 4.23 | 101.35 | 8.05 | 9.32 | 7.95 | 8.42 | 8.25 |
| 79.41 | 75.00 | 76.92 | 75.81 | 75.51 | 78.18 | 75.38 | 71.83 | 72.97 | 48.32 | 48.32 | 48.32 | 48.32 | 48.32 | 48.32 |
| 27.00 | 30.00 | 40.00 | 47.00 | 37.00 | 43.00 | 49.00 | 51.00 | 54.00 | 72.00 | 77.80 | 85.05 | 91.81 | 99.54 | 107.76 |
| -9.00 | -13.00 | -20.00 | -28.00 | -22.00 | -27.00 | -33.00 | -30.00 | -36.00 | -30.00 | -16.00 | -11.00 | -9.00 | -8.00 | -8.00 |
| -26.47 | -32.50 | -38.46 | -45.16 | -44.90 | -49.09 | -50.77 | -42.25 | -48.65 | -20.13 | -9.94 | -6.25 | -4.74 | -3.88 | -3.59 |
| -11.00 | -16.00 | -24.00 | -29.00 | -27.00 | -31.00 | -37.00 | -30.00 | -43.00 | -38.00 | -23.00 | -19.00 | -16.00 | -15.00 | -15.00 |
| – | 45.45 | 50.00 | 20.83 | -6.90 | 14.81 | 19.35 | -18.92 | 43.33 | -11.63 | -39.47 | -17.39 | -15.79 | -6.25 | – |
| 68.76 | 0.01 | 17.66 | 18.63 | 19.02 | 26.37 | 27.21 | 29.05 | 36.67 | 68.76 | 68.76 | 68.76 | 68.76 | 68.76 | 68.76 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Neuronetics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Neuronetics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Neuronetics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Neuronetics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Neuronetics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Neuronetics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Neuronetics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Neuronetics business model & stock analysis
Neuronetics SWOT Analysis
Strengths
Neuronetics Inc possesses several strengths that contribute to its success:
Neuronetics Inc has developed an innovative technology for the treatment of neurological disorders.
The company holds significant intellectual property rights, protecting its technology and products.
Neuronetics Inc has built a strong brand reputation in the medical device industry, resulting in customer trust and loyalty.
The company has a dedicated team of skilled professionals who contribute to the research, development, and commercialization of its products.
Weaknesses
Despite its strengths, Neuronetics Inc faces certain weaknesses that need to be addressed:
The company currently offers a limited range of products, which could restrict its market potential.
Neuronetics Inc primarily focuses on a specific market segment, which makes it vulnerable to fluctuations in that particular market.
Opportunities
There are several opportunities that Neuronetics Inc can capitalize on:
The company can explore new geographic markets and expand its product offerings to reach a larger customer base.
Neuronetics Inc can establish strategic partnerships and collaborations with other medical device companies to leverage their expertise and resources.
Threats
Neuronetics Inc should be cautious of the following threats:
The company operates in a highly competitive market with several established players, which may pose challenges in terms of market share and pricing.
Changes in regulatory requirements and policies can affect the manufacturing, distribution, and marketing of Neuronetics Inc's products.
Neuronetics Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Neuronetics Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Neuronetics historical P/E ratio, EBIT multiple, and P/S ratio
Neuronetics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Neuronetics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Neuronetics forecasts and price targets in September 2026
Analyst Price Targets 2026Neuronetics Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/11/2026 | Maintained | Buy | 52 | |
| 3/19/2026 | Maintained | Buy | 64 | |
| 8/6/2025 | Maintained | Buy | 64 | |
| 3/5/2025 | Maintained | Market Outperform | – | |
| 3/5/2025 | Maintained | Buy | 64 | |
| 8/14/2024 | Maintained | Market Outperform | – | |
| 8/13/2024 | Maintained | Buy | 64 | |
| 8/12/2024 | Downgrade | OutperformMarket Perform | – | |
| 5/14/2024 | Upgrade | Market PerformOutperform | – | |
| 3/6/2024 | Maintained | Overweight | 50 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Neuronetics Earnings Calls
Neuronetics Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/11/2026 | -0.13USD | - | 40.98 MUSD | - | 2026 Q2 |
| 5/12/2026 | -0.18USD | - | 34.87 MUSD | - | 2026 Q1 |
| 3/17/2026 | -0.11USD | - | 41.48 MUSD | - | 2025 Q4 |
| 11/12/2024 | -0.23USD | - | 19.52 MUSD | - | 2024 Q3 |
| 5/7/2024 | -0.30USD | - | 17.30 MUSD | - | 2024 Q1 |
| 3/5/2024 | -0.27USD | - | 20.16 MUSD | - | 2023 Q4 |
| 7/31/2023 | -0.32USD | - | 18.96 MUSD | - | 2023 Q2 |
| 5/10/2023 | -0.35USD | - | 16.90 MUSD | - | 2023 Q1 |
| 3/6/2023 | -0.39USD | - | 16.86 MUSD | - | 2022 Q4 |
| 11/8/2022 | -0.43USD | - | 15.24 MUSD | - | 2022 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Neuronetics stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Neuronetics shareholder structure
| % | Name |
|---|---|
31.44313% | |
13.00026% | |
7.34622% | |
3.95301% | |
3.91561% | |
3.87015% |
Neuronetics Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
30.30% | SEC ↗ | |
27.90% | SEC ↗ | |
26.20% | SEC ↗ | |
15.22% | SEC ↗ | |
14.90% | SEC ↗ | |
9.98% | SEC ↗ | |
9.80% | SEC ↗ | |
9.80% | SEC ↗ | |
8.80% | SEC ↗ | |
7.40% | SEC ↗ |
Neuronetics Executives and Management Board
9 members · avg. age 57 · 22 % women
Mr. W. Andrew Macan (52)
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
1.06 M USD
Management
Mr. Steven Pfanstiel (52)
Chief Financial Officer, Executive Vice President, Treasurer
Mr. Mark Klausner
Managing Partner
Board of Directors
Mr. Robert Cascella (71)
Independent Non-Executive Chairman of the Board
Mr. Glenn Muir (66)
Independent Director
Ms. Sheryl Conley (64)
Independent Director
Ms. Megan Rosengarten (48)
Independent Director
Mr. Sasha Cucuz (47)
Director
Dr. Avinash Amin (55)
Director
Neuronetics Supply Chain
Neuronetics Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | Greenbrook Tms | 0.90 | 0.88 | 0.88 | |
| 2 | 0.23 | 0.86 | 0.77 |
Frequently asked questions about Neuronetics
The business model of Neuronetics Inc. focuses on providing innovative medical technology solutions for patients suffering from psychiatric disorders, particularly major depressive disorder (MDD). As a leading medical device company, Neuronetics specializes in developing and commercializing NeuroStar® Advanced Therapy, an FDA-cleared non-invasive transcranial magnetic stimulation (TMS) system. This breakthrough treatment option offers a safe and effective alternative to traditional antidepressant medications. Neuronetics offers a comprehensive approach, combining their advanced TMS technology with clinical support and patient education. By addressing the unmet needs of individuals with MDD, Neuronetics aims to improve the quality of life for patients and enhance mental health treatment outcomes.
Neuronetics Inc is primarily active in the healthcare industry.
The main competitors of Neuronetics Inc in the market include companies such as MagVenture, BrainsWay, and Fisher Wallace.
Neuronetics Inc is a reputable medical device company founded in 2003. Headquartered in Pennsylvania, the company focuses on developing innovative treatments for psychiatric disorders, specifically major depressive disorder (MDD). Neuronetics Inc is widely recognized for its groundbreaking invention, NeuroStar Advanced Therapy system, which utilizes transcranial magnetic stimulation (TMS) to alleviate depressive symptoms. With a commitment to providing non-invasive and effective solutions, Neuronetics Inc has gained significant recognition within the medical community. Over the years, the company has strived to improve patients' well-being and enhance mental health treatment options, solidifying its position as a leader in the field of neuromodulation therapies.
Neuronetics Inc has achieved significant milestones since its inception. The company introduced the NeuroStar Advanced Therapy, an FDA-cleared transcranial magnetic stimulation (TMS) system, which has revolutionized the treatment of depression. Neuronetics Inc expanded its reach by attaining various regulatory clearances globally, allowing patients worldwide to benefit from TMS therapy. The company also secured multiple strategic partnerships, further enhancing its market presence and advancing the field of neuromodulation. Neuronetics Inc's dedication to research and innovation has led to numerous clinical publications highlighting the effectiveness of NeuroStar TMS therapy. With its relentless pursuit of advancing psychiatric care, Neuronetics Inc continues to make significant strides in improving patient outcomes and quality of life.
Neuronetics Inc is primarily present in the United States.
Neuronetics Inc represents values of innovation, patient-centricity, and continuous improvement. With a corporate philosophy focused on developing advanced solutions for mental health disorders, Neuronetics Inc strives to improve the lives of individuals suffering from depression. The company's NeuroStar Advanced Therapy system, utilizing transcranial magnetic stimulation, is a testament to their commitment to innovation and providing effective treatment options. By placing patients at the center of their efforts, Neuronetics Inc aims to enhance mental health outcomes and restore hope for those in need.
Analysts currently set an average price target of 3.06 USD for the Neuronetics stock (median: 3.06 USD), implying +6.2 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the Neuronetics stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Neuronetics to generate revenue of 161.77 M USD and earnings per share of -0.34 USD.
Converted at the current exchange rate, the Neuronetics share trades at 2.48 EUR (2.88 USD).
The Neuronetics share (STIM) is listed on 3 stock exchanges, including: NASDAQ (STIM), Frankfurt (NRC.F), München (NRC.MU).
Neuronetics Inc. is a leading manufacturer of medical devices that help patients with mental disorders such as depression. The company is headquartered in Malvern, Pennsylvania, USA. Neuronetics Inc.'s business model is based on selling devices for Transcranial Magnetic Stimulation (TMS). TMS is a non-invasive method for treating severe depression in patients who have not responded to other treatment methods. The method uses high-intensity magnetic pulses to stimulate the brain, resulting in a reduction of symptoms. The company's core product is the NeuroStar Advanced Therapy System (ATS). The system consists of a TMS device and a specialized treatment chair. The chair can be individually adjusted to meet the patient's needs for optimal treatment. The NeuroStar ATS is the first TMS therapy in the USA to be approved by the Food and Drug Administration (FDA) for use in patients with depression. Neuronetics Inc. distributes its products through a broad sales structure. The company has its own sales representatives who handle the sales and marketing of the products in the USA and Europe. In addition, Neuronetics Inc. collaborates with distribution partners to distribute its products in countries where the company is not directly represented. The company also has a strong research component. Neuronetics Inc. has established a network of clinics and research institutions that participate in clinical studies on TMS therapy. The company also supports independent researchers working on the development of new applications of TMS therapy. Neuronetics Inc. works closely with health insurance companies and private insurers to ensure that its products can be used by as many patients as possible. The company maintains constant contact with healthcare decision-makers and organizes regular conferences and workshops to inform about the possibilities of TMS therapy. In summary, Neuronetics Inc. is an innovative company dedicated to the treatment of patients with severe depression. The company offers a high-quality and safe treatment system that has already been successfully used by many patients. With its broad sales structure and strong research component, Neuronetics Inc. is well positioned to continue to play a leading role in the market for TMS therapy.
The expected revenue of Neuronetics is 161.77 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Neuronetics is -23.38 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Neuronetics is currently -8.47. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Neuronetics stock.
The price-to-sales ratio (P/S) of Neuronetics is currently 1.22. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Neuronetics stock.
The Eulerpool Quality Score for Neuronetics is 3/10.
The ISIN of Neuronetics is US64131A1051. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Neuronetics is A2JPMY. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Neuronetics is STIM. The ticker symbol is used to trade Neuronetics shares on the stock exchange.
Neuronetics paid dividends every year for the past 0 years.
Neuronetics is assigned to the 'Health' sector.
The dividends of Neuronetics are distributed in USD.
Neuronetics stock
Neuronetics Peer Group
Neuronetics Ticker
Neuronetics FIGI
All fundamentals and in-depth analysis of Neuronetics
Our stock analysis for Neuronetics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neuronetics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.